




Instance: composition-en-18a94f164fb1fa919f787ce6c80174e7
InstanceOf: CompositionUvEpi
Title: "Composition for zytiga Package Leaflet"
Description:  "Composition for zytiga Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd370afcf60e0cd86208881322b9eabee)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - zytiga"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What ZYTIGA is and what it is used for</li>
<li>What you need to know before you take ZYTIGA</li>
<li>How to take ZYTIGA</li>
<li>Possible side effects</li>
<li>How to store ZYTIGA</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What zytiga is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What zytiga is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ZYTIGA contains a medicine called abiraterone acetate. It is used to treat prostate cancer in adult men 
that has spread to other parts of the body. ZYTIGA stops your body from making testosterone; this can 
slow the growth of prostate cancer.
When ZYTIGA is prescribed for the early stage of disease where it is still responding to hormone 
therapy, it is used with a treatment that lowers testosterone (androgen deprivation therapy).
When you take this medicine your doctor will also prescribe another medicine called prednisone or 
prednisolone. This is to lower your chances of getting high blood pressure, having too much water in 
your body (fluid retention), or having reduced levels of a chemical known as potassium in your blood.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take zytiga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take zytiga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Do not take ZYTIGA</h2>
<p>if you are allergic to abiraterone acetate or any of the other ingredients of this medicine (listed 
in section 6).
-
if you are a woman, especially if pregnant. ZYTIGA is for use in male patients only.
-
if you have severe liver damage.
-
in combination with Ra-223 (which is used to treat prostate cancer).
Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or 
pharmacist before taking this medicine.
Warnings and precautions
Talk to your doctor or pharmacist before taking this medicine:
-
if you have liver problems
-
if you have been told you have high blood pressure or heart failure or low blood potassium (low 
blood potassium may increase the risk of heart rhythm problems)
-
if you have had other heart or blood vessel problems
-
if you have an irregular or rapid heart rate
-
if you have shortness of breath
-
if you have gained weight rapidly
-
if you have swelling in the feet, ankles, or legs
-
if you have taken a medicine known as ketoconazole in the past for prostate cancer
-
about the need to take this medicine with prednisone or prednisolone
-
about possible effects on your bones
-
if you have high blood sugar.
Tell your doctor if you have been told you have any heart or blood vessel conditions, including heart 
rhythm problems (arrhythmia), or are being treated with medicines for these conditions.
Tell your doctor if you have yellowing of the skin or eyes, darkening of the urine, or severe nausea or 
vomiting, as these could be signs or symptoms of liver problems. Rarely, failure of the liver to 
function (called acute liver failure) may occur, which can lead to death.
Decrease in red blood cells, reduced sex drive (libido), muscle weakness and/or muscle pain may 
occur.
ZYTIGA must not be given in combination with Ra-223 due to a possible increase in the risk of bone 
fracture or death. 
If you plan to take Ra-223 following treatment with ZYTIGA and prednisone/prednisolone, you must 
wait 5 days before starting treatment with Ra-223. If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking this 
medicine.
Blood monitoring
ZYTIGA may affect your liver, and you may not have any symptoms. When you are taking this 
medicine, your doctor will check your blood periodically to look for any effects on your liver.
Children and adolescents
This medicine is not for use in children and adolescents. If ZYTIGA is accidentally ingested by a child 
or adolescent, go to the hospital immediately and take the package leaflet with you to show to the 
emergency doctor.
Other medicines and ZYTIGA
Ask your doctor or pharmacist for advice before taking any medicine.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. This is important because ZYTIGA may increase the effects of a number of medicines 
including heart medicines, tranquilisers, some medicines for diabetes, herbal medicines (e.g., 
St John s wort) and others. Your doctor may want to change the dose of these medicines. Also, some 
medicines may increase or decrease the effects of ZYTIGA. This may lead to side effects or to 
ZYTIGA not working as well as it should.
Androgen deprivation treatment may increase the risk of heart rhythm problems. Tell your doctor if 
you are receiving medicine
-
used to treat heart rhythm problems (e.g. quinidine, procainamide, amiodarone and sotalol);
-
known to increase the risk of heart rhythm problems [e.g. methadone (used for pain relief and 
part of drug addiction detoxification), moxifloxacin (an antibiotic), antipsychotics (used for 
serious mental illnesses)].
Tell your doctor if you are taking any of the medicines listed above.
ZYTIGA with food
-
This medicine must not be taken with food (see section 3,  Taking this medicine ).
-
Taking ZYTIGA with food may cause side effects.
Pregnancy and breast-feeding
ZYTIGA is not for use in women.
-
This medicine may cause harm to the unborn child if it is taken by women who are 
pregnant.
-
Women who are pregnant or who may be pregnant should wear gloves if they need to 
touch or handle ZYTIGA.
-
If you are having sex with a woman who can become pregnant, use a condom and another 
effective birth control method.
-
If you are having sex with a pregnant woman, use a condom to protect the unborn child.
Driving and using machines
This medicine is not likely to affect your being able to drive and use any tools or machines.
ZYTIGA contains lactose and sodium
-
ZYTIGA contains lactose. If you have been told by your doctor that you have an intolerance to 
some sugars, contact your doctor before taking this medicinal product.
-
This medicine contains 27.2 mg sodium (main component of cooking/table salt) in a four tablet
daily dose. This is equivalent to 1.36% of the recommended maximum daily dietary intake of 
sodium for an adult.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take zytiga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take zytiga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure.
How much to take
The recommended dose is 1 000 mg (four tablets) once a day.
Taking this medicine
-
Take this medicine by mouth.
-
Do not take ZYTIGA with food. Taking ZYTIGA with food may cause more of the medicine 
to be absorbed by the body than is needed and this may cause side effects.
-
Take ZYTIGA tablets as a single dose once daily on an empty stomach. ZYTIGA must be taken
at least two hours after eating and food must not be eaten for at least one hour after taking 
ZYTIGA. (see section 2,  ZYTIGA with food ).
-
Swallow the tablets whole with water.
-
Do not break the tablets.
-
ZYTIGA is taken with a medicine called prednisone or prednisolone. Take the prednisone or 
prednisolone exactly as your doctor has told you.
-
You need to take prednisone or prednisolone every day while you are taking ZYTIGA.
-
The amount of prednisone or prednisolone you take may need to change if you have a medical 
emergency. Your doctor will tell you if you need to change the amount of prednisone or 
prednisolone you take. Do not stop taking prednisone or prednisolone unless your doctor tells 
you to.
Your doctor may also prescribe other medicines while you are taking ZYTIGA and prednisone or 
prednisolone.
If you take more ZYTIGA than you should
If you take more than you should, talk to your doctor or go to a hospital immediately.
If you forget to take ZYTIGA
-
If you forget to take ZYTIGA or prednisone or prednisolone, take your usual dose the following 
day.
-
If you forget to take ZYTIGA or prednisone or prednisolone for more than one day, talk to your 
doctor without delay.
If you stop taking ZYTIGA
Do not stop taking ZYTIGA or prednisone or prednisolone unless your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking ZYTIGA and see a doctor immediately if you notice any of the following:
-
Muscle weakness, muscle twitches or a pounding heart beat (palpitations). These may be signs 
that the level of potassium in your blood is low.
Other side effects include:
Very common (may affect more than 1 in 10 people):
Fluid in your legs or feet, low blood potassium, liver function test increases, high blood pressure, 
urinary tract infection, diarrhoea.
Common (may affect up to 1 in 10 people):
High fat levels in your blood, chest pain, irregular heart beat (atrial fibrillation), heart failure, rapid 
heart rate, severe infections called sepsis, bone fractures, indigestion, blood in urine, rash.
Uncommon (may affect up to 1 in 100 people):
Adrenal gland problems (related to salt and water problems), abnormal heart rhythm (arrhythmia), 
muscle weakness and/or muscle pain.
Rare (may affect up to 1 in 1 000 people):
Lung irritation (also called allergic alveolitis).
Failure of the liver to function (also called acute liver failure).
Not known (frequency cannot be estimated from the available data):
Heart attack, changes in ECG - electrocardiogram (QT prolongation), and serious allergic reactions 
with difficulty swallowing or breathing, swollen face, lips, tongue or throat, or an itchy rash.
Bone loss may occur in men treated for prostate cancer. ZYTIGA in combination with prednisone or 
prednisolone may increase bone loss.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store zytiga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store zytiga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>-
Keep this medicine out of the sight and reach of children.
-
Do not use this medicine after the expiry date which is stated on the carton and the bottle label. 
The expiry date refers to the last day of that month.
-
This medicinal product does not require any special storage conditions.
-
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist 
how to throw away medicines you no longer use. These measures will help to protect the 
environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>What ZYTIGA contains</h2>
<h2>The active substance is abiraterone acetate. Each tablet contains 250 mg abiraterone acetate.</h2>
<p>The other ingredients are microcrystalline cellulose, croscarmellose sodium, lactose 
monohydrate, magnesium stearate, povidone (K29/K32), colloidal anhydrous silica, and sodium 
laurilsulfate (see section 2,  ZYTIGA contains lactose and sodium ).
What ZYTIGA looks like and contents of the pack
-
ZYTIGA tablets are white to off-white, oval shaped (15.9 mm long x 9.5 mm wide), with 
 AA250  written on one side.
-
The tablets are provided in a plastic bottle with a child-resistant closure. Each bottle contains 
120 tablets. Each carton contains one bottle.
Marketing Authorisation Holder
Janssen-Cilag International NV
Turnhoutseweg B-2340 Beerse
Belgium
Manufacturer
Janssen-Cilag SpA
Via C. Janssen
Borgo San Michele
I-04100 Latina, Italy
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:
Belgi /Belgique/Belgien
Janssen-Cilag NV
Tel/T l: +32 14 64 94 janssen@jacbe.jnj.com
Lietuva
UAB "JOHNSON &amp; JOHNSON"
Tel: +370 5 278 68 lt@its.jnj.com</p>
<p>&amp;    <br />
 .: +359 2 489 94 jjsafety@its.jnj.com
Luxembourg/Luxemburg
Janssen-Cilag NV
Tel/T l: +32 14 64 94 janssen@jacbe.jnj.com
 esk  republika
Janssen-Cilag s.r.o.
Tel. +420 227 012 Magyarorsz g
Janssen-Cilag Kft.
Tel.: +36 1 884 2janssenhu@its.jnj.com
Danmark
Janssen-Cilag A/S
Tlf: +45 45 94 82 jacdk@its.jnj.com
Malta
AM MANGION LTD.
Tel: +356 2397 6Deutschland
Janssen-Cilag GmbH
Tel: +49 2137 955 jancil@its.jnj.com
Nederland
Janssen-Cilag B.V.
Tel: +31 76 711 1janssen@jacnl.jnj.com
Eesti
UAB "JOHNSON &amp; JOHNSON" Eesti filiaal
Tel: +372 617 7ee@its.jnj.com
Norge
Janssen-Cilag AS
Tlf: +47 24 12 65 jacno@its.jnj.com</p>
<p>Janssen-Cilag    . . . .
T : +30 210 80 90  sterreich
Janssen-Cilag Pharma GmbH
Tel: +43 1 610 Espa a
Janssen-Cilag, S.A.
Tel: +34 91 722 81 contacto@its.jnj.com
Polska
Janssen-Cilag Polska Sp. z o.o.
Tel.+48 22 237 60 France
Janssen-Cilag
T l: 0 800 25 50 75 / +33 1 55 00 40 medisource@its.jnj.com
Portugal
Janssen-Cilag Farmac utica, Lda.
Tel: +351 214 368 Hrvatska
Johnson &amp; Johnson S.E. d.o.o.
Tel: +385 1 6610 jjsafety@JNJCR.JNJ.com
Rom nia
Johnson &amp; Johnson Rom nia SRL
Tel: +40 21 207 1Ireland
Janssen Sciences Ireland UC
Tel: +353 1 800 709 Slovenija
Johnson &amp; Johnson d.o.o.
Tel: +386 1 401 18 Janssen_safety_slo@its.jnj.com
 sland
Janssen-Cilag AB
c/o Vistor hf.
S mi: +354 535 7janssen@vistor.is
Slovensk  republika
Johnson &amp; Johnson, s.r.o.
Tel: +421 232 408 Italia
Janssen-Cilag SpA
Tel: 800.688.777 / +39 02 2510 1
janssenita@its.jnj.com
Suomi/Finland
Janssen-Cilag Oy
Puh/Tel: +358 207 531 jacfi@its.jnj.com</p>
<p>: +357 22 207 Sverige
Janssen-Cilag AB
Tfn: +46 8 626 50 jacse@its.jnj.com
Latvija
UAB "JOHNSON &amp; JOHNSON" fili le Latvij 
Tel: +371 678 93lv@its.jnj.com
United Kingdom (Northern Ireland)
Janssen Sciences Ireland UC
Tel: +44 1 494 567 This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu.
Package leaflet: Information for the user
ZYTIGA 500 mg film-coated tablets
abiraterone acetate
Read all of this leaflet carefully before you start taking this medicine because it contains 
important information for you.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, 
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This includes any possible side 
effects not listed in this leaflet. See section 4.</p>         </div>"""      



Instance: composition-da-18a94f164fb1fa919f787ce6c80174e7
InstanceOf: CompositionUvEpi
Title: "Composition for zytiga Package Leaflet"
Description:  "Composition for zytiga Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpd370afcf60e0cd86208881322b9eabee)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - zytiga"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Se den nyeste indlægsseddel på www.indlaegsseddel.dk</p>         </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage ZYTIGA
3. Sådan skal du tage ZYTIGA
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What zytiga is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What zytiga is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>ZYTIGA indeholder lægemidlet abirateronacetat. Det anvendes til at behandle voksne mænd med 
prostatacancer, som har spredt sig til andre dele af kroppen. ZYTIGA hindrer kroppen i at fremstille 
testosteron og kan derved nedsætte væksten af prostatacancer.
Når ZYTIGA anvendes i sygdommens tidlige fase, hvor den stadig reagerer på hormonbehandling, 
anvendes det sammen med en behandling, der nedsætter dannelsen af testosteron (androgen 
deprivationsbehandling).
Mens du er i behandling med dette lægemiddel, vil din læge også ordinere enten prednison eller 
prednisolon til dig. Derved nedsættes risikoen for, at du får højt blodtryk, for meget væske i kroppen 
(væskeretention) eller nedsat indhold af mineralet kalium i blodet.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take zytiga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take zytiga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Tag ikke ZYTIGA</h2>
<p>hvis du er allergisk over for abirateronacetat eller et af de øvrige indholdsstoffer i ZYTIGA 
(angivet i punkt 6).
-
hvis du er en kvinde, og især hvis du er gravid. ZYTIGA er udelukkende beregnet til brug hos 
mandlige patienter.
-
hvis du har svære leverskader.
-
i kombination med Ra-223 (som anvendes til behandling af prostatacancer).
Tag ikke dette lægemiddel, hvis noget af dette gælder for dig. Hvis du er i tvivl, så spørg din læge eller 
apotekspersonalet, inden du tager dette lægemiddel.
Advarsler og forsigtighedsregler
Kontakt lægen eller apotekspersonalet, før du tager ZYTIGA:
-
hvis du har leverproblemer
65
-
hvis du har fået at vide, at du har højt blodtryk eller hjertesvigt eller lavt indhold af kalium i 
blodet (lavt indhold af kalium i blodet kan øge risikoen for problemer med hjerterytmen)
-
hvis du har haft andre problemer med hjerte eller blodkar
-
hvis du har en uregelmæssig eller hurtig puls
-
hvis du er kortåndet
-
hvis du har taget hurtigt på i vægt
-
hvis du har hævede fødder, ankler eller ben
-
hvis du tidligere har taget ketoconazol mod prostatacancer
-
om nødvendigheden af at tage dette lægemiddel sammen med prednison eller prednisolon
-
om hvordan lægemidlet kan påvirke knoglerne
-
hvis du har højt blodsukker.
Fortæl det til lægen, hvis du har fået at vide, at du har sygdomme, der vedrører hjertet eller 
blodkarrene, herunder problemer med hjerterytmen (arytmi), eller hvis du får lægemidler for sådanne 
sygdomme.
Fortæl det til lægen, hvis du får gulfarvning af huden eller øjnene, mørk urin eller svær kvalme eller 
opkastning, eftersom dette kan være tegn eller symptomer på leverproblemer. I sjældne tilfælde kan 
leveren holde op med at fungere (dette kaldes akut leversvigt), hvilket kan være dødeligt.
Nedsat antal røde blodlegemer, nedsat sexlyst (libido) samt muskelsvaghed og/eller muskelsmerter 
kan forekomme.
ZYTIGA må ikke gives i kombination med Ra-223 på grund af en mulig forøgelse af risikoen for 
knoglebrud eller dødsfald.
Hvis du planlægger at tage Ra-223 efter behandling med ZYTIGA og prednison/prednisolon, skal du 
vente 5 dage, før du starter behandling med Ra-223. Spørg lægen eller på apoteket, før du tager dette lægemiddel, hvis du er usikker på, om noget af dette 
gælder for dig.
Blodprøvekontrol
ZYTIGA kan påvirke leveren, uden at du får symptomer. Når du tager dette lægemiddel, skal du have 
taget jævnlige blodprøver hos lægen for at få kontrolleret, om medicinen påvirker din lever.
Børn og unge
Dette lægemiddel er ikke beregnet til børn og unge. Hvis et barn eller en ung person ved et uheld 
kommer til at tage ZYTIGA, skal I straks tage på hospitalet og medbringe indlægssedlen, så I kan vise 
den til lægen på skadestuen.
Brug af anden medicin sammen med ZYTIGA
Spørg din læge eller apoteket til råds, inden du tager nogen form for medicin.
Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for 
nylig. Det er vigtigt, fordi ZYTIGA kan forstærke virkningen af en række lægemidler, herunder blandt 
andet hjertemedicin, beroligende midler, visse lægemidler mod diabetes, naturlægemidler (f.eks. 
perikon) og anden medicin. Din læge vil måske ændre dosis af disse lægemidler. Desuden kan nogle 
lægemidler forstærke eller nedsætte virkningen af ZYTIGA. Det kan medføre bivirkninger eller 
resultere i, at ZYTIGA ikke virker så godt, som det skal.
Androgen deprivationsbehandling kan øge risikoen for problemer med hjerterytmen. Fortæl det til 
lægen, hvis du får medicin, som
-
bruges til at behandle problemer med hjerterytmen (f.eks. kinidin, procainamid, amiodaron og 
sotalol).
66
-
vides at øge risikoen for problemer med hjerterytmen [f.eks. methadon (som anvendes til 
smertelindring samt i forbindelse med afvænning ved stofmisbrug), moxifloxacin (et 
antibiotikum), antipsykotika (som anvendes til alvorlige psykiske lidelser)].
Fortæl det til din læge, hvis du tager nogen af de ovenstående lægemidler.
Brug af ZYTIGA sammen med mad
-
Dette lægemiddel må ikke tages sammen med mad (se "Sådan skal du tage medicinen" under 
punkt 3).
-
Indtagelse af ZYTIGA sammen med mad kan give bivirkninger.
Graviditet og amning
ZYTIGA er ikke beregnet til kvinder.
-
Dette lægemiddel kan skade fostret, hvis det tages af kvinder, som er gravide.
-
Kvinder, som er gravide, eller kvinder, som måske kan være gravide, skal anvende 
handsker, hvis det er nødvendigt, at de rører ved eller håndterer ZYTIGA.
-
Brug kondom og en anden sikker præventionsmetode hvis du dyrker sex med en kvinde, 
som kan blive gravid. 
-
Brug kondom for at beskytte fostret, hvis du har sex med en gravid kvinde.
Trafik- og arbejdssikkerhed
Dette lægemiddel påvirker sandsynligvis ikke arbejdssikkerheden eller evnen til at færdes i trafikken.
ZYTIGA indeholder lactose og natrium
-
ZYTIGA indeholder lactose. Kontakt lægen, før du tager dette lægemiddel, hvis lægen har 
fortalt dig, at du ikke tåler visse sukkerarter.
-
Dette lægemiddel indeholder 27,2 mg natrium (hoved komponent af madlavnings-/bordsalt) pr. 
daglig dosis på fire tabletter. Dette svarer til 1,36 % af den anbefalede maximale daglige 
indtagelse af natrium for en voksen.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take zytiga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take zytiga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet.
Hvor meget
Den anbefalede dosis er 1 000 mg (fire tabletter) en gang dagligt.
Sådan skal du tage medicinen
-
Dette lægemiddel skal indtages gennem munden.
-
ZYTIGA må ikke tages sammen med mad. Hvis du tager ZYTIGA sammen med mad, kan 
det medføre, at mere af medicinen optages i kroppen, end der er behov for, og det kan give 
bivirkninger.
-
Tag ZYTIGA-tabletterne som en enkeltdosis én gang dagligt på tom mave. ZYTIGA skal tages 
mindst to timer efter et måltid, og du må ikke spise før mindst én time efter at have taget 
ZYTIGA (se "Brug af ZYTIGA sammen med mad" under punkt 2).
-
Synk tabletterne hele med vand.
-
Tabletterne må ikke deles.
-
ZYTIGA skal tages sammen med lægemidlet prednison eller prednisolon. Tag prednison eller 
prednisolon nøjagtigt efter lægens anvisning.
-
Du skal tage prednison eller prednisolon dagligt, mens du tager ZYTIGA.
-
Den mængde prednison eller prednisolon, som du får, skal måske ændres hvis der opstår en akut 
medicinsk tilstand. Din læge vil give dig besked, hvis du skal ændre din dosis af prednison eller 
prednisolon. Du må ikke holde op med at tage prednison eller prednisolon, med mindre lægen 
anbefaler det.
67
Lægen kan også foreskrive anden medicin under din behandling med ZYTIGA og prednison eller 
prednisolon.
Hvis du har taget for meget ZYTIGA
Kontakt straks lægen eller skadestuen, hvis du har taget for mange tabletter.
Hvis du har glemt at tage ZYTIGA
-
Hvis du glemmer at tage ZYTIGA, prednison eller prednisolon, skal du tage den sædvanlige 
dosis næste dag.
-
Kontakt straks lægen, hvis du har glemt at tage ZYTIGA, prednison eller prednisolon i mere 
end en dag.
Hvis du holder op med at tage ZYTIGA
Hold ikke op med at tage ZYTIGA, prednison eller prednisolon, medmindre lægen anbefaler det.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
Hold op med at tage ZYTIGA, og kontakt straks en læge, hvis du bemærker følgende:
-
Muskelsvaghed, muskeltrækninger eller hjertebanken (palpitationer). Dette kan være tegn på, at 
blodets indhold af kalium er lavt.
Andre bivirkninger:
Meget almindelige (kan berøre flere end 1 ud af 10 behandlede):
Væske i ben eller fødder, lavt indhold af kalium i blodet, forhøjede leverfunktionsprøver, højt 
blodtryk, urinvejsinfektion, diaré.
Almindelige (kan berøre op til 1 ud af 10 behandlede):
Højt indhold af fedt i blodet, smerter i brystet, uregelmæssig puls (atrieflimren), hjertesvigt, hurtig 
puls, alvorlige infektioner, som kaldes blodforgiftning (sepsis), knoglebrud, mavebesvær, blod i 
urinen, udslæt.
Ikke almindelige (kan berøre op til 1 ud af 100 patienter):
Binyrebarksvigt (relateret til problemer med væske- og saltbalancen), unormal hjerterytme (arytmi), 
muskelsvaghed og/eller muskelsmerter.
Sjældne (kan berøre op til 1 ud af 1 000 patienter):
Lungeirritation (også kaldet allergisk alveolitis).
Ophør af leverens funktion (også kaldet akut leversvigt).
Ikke kendt (hyppigheden kan ikke estimeres ud fra forhåndenværende data):
Hjerteanfald, ændringer i elektrokardiogram (QT-forlængelse i EKG) og alvorlige allergiske 
reaktioner, med synke- eller vejrtrækningsbesvær, hævelse i ansigt, læber, tunge eller svælg eller 
kløende udslæt.
Knogletab kan forekomme hos mænd, der behandles for prostatacancer. ZYTIGA i kombination med 
prednison eller prednisolon kan øge knogletabet.
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel.
68</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store zytiga"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store zytiga"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>-
Opbevar lægemidlet utilgængeligt for børn.
-
Brug ikke lægemidlet efter den udløbsdato, der står på æsken og på etiketten på beholderen. 
Udløbsdatoen er den sidste dag i den nævnte måned.
-
Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.
-
Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du 
ikke smide medicinrester i afløbet, toilettet eller skraldespanden.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>ZYTIGA indeholder:</h2>
<h2>Aktivt stof: abirateronacetat. En tablet indeholder 250 mg abirateronacetat.</h2>
<p>Øvrige indholdsstoffer: mikrokrystallinsk cellulose, croscarmellosenatrium, lactosemonohydrat, 
magnesiumstearat, povidon (K29/K32), kolloid vandfri silica, natriumlaurilsulfat; (se "ZYTIGA 
indeholder lactose og natrium" under punkt 2).
Udseende og pakningsstørrelser
-
ZYTIGA tabletter er hvide til offwhite, ovale tabletter (15,9 mm lange x 9,5 mm brede) med 
“AA250" skrevet på den ene side.
-
Tabletterne udleveres i en plastbeholder med børnesikret lukke. Hver beholder indeholder 
120 tabletter. Hver æske indeholder 1 beholder.
Indehaver af markedsføringstilladelsen
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgien
Fremstiller
Janssen-Cilag SpA
Via C. Janssen
Borgo San Michele
I-04100 Latina, Italien
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
Janssen-Cilag NV
Tel/Tél: +32 14 64 94 11
janssen@jacbe.jnj.com
Lietuva
UAB "JOHNSON &amp; JOHNSON"
Tel: +370 5 278 68 88
lt@its.jnj.com
България
„Джонсън &amp; Джонсън България" ЕООД
Тел.: +359 2 489 94 00
jjsafety@its.jnj.com
Luxembourg/Luxemburg
Janssen-Cilag NV
Tel/Tél: +32 14 64 94 11
janssen@jacbe.jnj.com
Česká republika
Janssen-Cilag s.r.o.
Tel. +420 227 012 227
Magyarország
Janssen-Cilag Kft.
Tel.: +36 1 884 2858
janssenhu@its.jnj.com
69
Danmark
Janssen-Cilag A/S
Tlf: +45 45 94 82 82
jacdk@its.jnj.com
Malta
AM MANGION LTD.
Tel: +356 2397 6000
Deutschland
Janssen-Cilag GmbH
Tel: +49 2137 955 955
jancil@its.jnj.com
Nederland
Janssen-Cilag B.V.
Tel: +31 76 711 1111
janssen@jacnl.jnj.com
Eesti
UAB "JOHNSON &amp; JOHNSON" Eesti filiaal
Tel: +372 617 7410
ee@its.jnj.com
Norge
Janssen-Cilag AS
Tlf: +47 24 12 65 00
jacno@its.jnj.com
Ελλάδα
Janssen-Cilag Φαρμακευτική Α.Ε.Β.Ε.
Tηλ: +30 210 80 90 000
Österreich
Janssen-Cilag Pharma GmbH
Tel: +43 1 610 300
España
Janssen-Cilag, S.A.
Tel: +34 91 722 81 00
contacto@its.jnj.com
Polska
Janssen-Cilag Polska Sp. z o.o.
Tel.+48 22 237 60 00
France
Janssen-Cilag
Tél: 0 800 25 50 75 / +33 1 55 00 40 03
medisource@its.jnj.com
Portugal
Janssen-Cilag Farmacêutica, Lda.
Tel: +351 214 368 600
Hrvatska
Johnson &amp; Johnson S.E. d.o.o.
Tel: +385 1 6610 700
jjsafety@JNJCR.JNJ.com
România
Johnson &amp; Johnson România SRL
Tel: +40 21 207 1800
Ireland
Janssen Sciences Ireland UC
Tel: +353 1 800 709 122
Slovenija
Johnson &amp; Johnson d.o.o.
Tel: +386 1 401 18 00
Janssen_safety_slo@its.jnj.com
Ísland
Janssen-Cilag AB
c/o Vistor hf.
Sími: +354 535 7000
janssen@vistor.is
Slovenská republika
Johnson &amp; Johnson, s.r.o.
Tel: +421 232 408 400
Italia
Janssen-Cilag SpA
Tel: 800.688.777 / +39 02 2510 1
janssenita@its.jnj.com
Suomi/Finland
Janssen-Cilag Oy
Puh/Tel: +358 207 531 300
jacfi@its.jnj.com
Κύπρος
Βαρνάβας Χατζηπαναγής Λτδ
Τηλ: +357 22 207 700
Sverige
Janssen-Cilag AB
Tfn: +46 8 626 50 00
jacse@its.jnj.com
70
Latvija
UAB "JOHNSON &amp; JOHNSON" filiāle Latvijā
Tel: +371 678 93561
lv@its.jnj.com
United Kingdom (Northern Ireland)
Janssen Sciences Ireland UC
Tel: +44 1 494 567 444
Denne indlægsseddel blev senest ændret
Andre informationskilder
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/.
71
Indlægsseddel: Information til brugeren
ZYTIGA 500 mg filmovertrukne tabletter
abirateronacetat
Læs denne indlægsseddel grundigt, inden du begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger.
-
Gem indlægssedlen. Du kan få brug for at læse den igen.
-
Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide.
-
Lægen har ordineret dette lægemiddel til dig personligt. Lad derfor være med at give medicinen 
til andre. Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har.
-
Kontakt lægen eller apotekspersonalet, hvis du får bivirkninger, herunder bivirkninger, som 
ikke er nævnt i denne indlægsseddel. Se punkt 4. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-18a94f164fb1fa919f787ce6c80174e7
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for zytiga Package Leaflet for language en"
Description: "ePI document Bundle for zytiga Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-18a94f164fb1fa919f787ce6c80174e7"
* entry[0].resource = composition-en-18a94f164fb1fa919f787ce6c80174e7

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp18a94f164fb1fa919f787ce6c80174e7"
* entry[=].resource = mp18a94f164fb1fa919f787ce6c80174e7
                            
                    
Instance: bundlepackageleaflet-da-18a94f164fb1fa919f787ce6c80174e7
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for zytiga Package Leaflet for language da"
Description: "ePI document Bundle for zytiga Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-18a94f164fb1fa919f787ce6c80174e7"
* entry[0].resource = composition-da-18a94f164fb1fa919f787ce6c80174e7

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp18a94f164fb1fa919f787ce6c80174e7"
* entry[=].resource = mp18a94f164fb1fa919f787ce6c80174e7
                            
                    



Instance: mp18a94f164fb1fa919f787ce6c80174e7
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product ZYTIGA 250 mg tablets"
Description: "ZYTIGA 250 mg tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/11/714/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "ZYTIGA 250 mg tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 18a94f164fb1fa919f787ce6c80174e7ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "zytiga"

* status = #current
* mode = #working

* title = "List of all ePIs associated with zytiga"

* subject = Reference(mpd370afcf60e0cd86208881322b9eabee)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#zytiga "zytiga"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-18a94f164fb1fa919f787ce6c80174e7) // zytiga en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-18a94f164fb1fa919f787ce6c80174e7) // zytiga da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-18a94f164fb1fa919f787ce6c80174e7
InstanceOf: List

* insert 18a94f164fb1fa919f787ce6c80174e7ListRuleset
    